The power of FDG PET to detect treatment effects is increased by glucose correction using a Michaelis constant

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages

  Williams, Simon Peter ^a   Flores Mercado, Judith E ^a   Baudy, Andreas R ^a   Port, Ruediger E ^a   Bengtsson, Thomas ^a  

^a GENENTECH INC   (United States)

Author keywords

FDG PET; Glucose bias; Glucose correction; Michaelis Menten; Response to treatment

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE TRANSPORTER 1;

ANALYTICAL ERROR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; FALSE POSITIVE RESULT; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; IMMUNOFLUORESCENCE; MATHEMATICAL MODEL; MICHAELIS CONSTANT; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STATISTICAL ANALYSIS;

EID: 84875912288     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-35     Document Type: Article

References (35)

1. Wahl RL, Henry CA, Ethier SP: Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology 1992, 183(3):643-647.
2. Lindholm P, Minn H, Leskinen-Kallio S, Bergman J, Ruotsalainen U, Joensuu H: Influence of the blood glucose concentration on FDG uptake in cancer-a PET study. Journal of nuclear medicine: official publication. Soc Nucl Med 1993, 34(1):1-6.
3. Diederichs CG, Staib L, Glatting G, Beger HG, Reske SN: FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 1998, 39(6):1030-1033.
4. Torizuka T, Zasadny KR, Wahl RL: Diabetes decreases FDG accumulation in primary lung cancer. Clin Positron Imag Offic J Inst Clin PET 1999, 2(5):281-287.
5. Zhuang HM, Cortes-Blanco A, Pourdehnad M, Adam LE, Yamamoto AJ, Martinez-Lazaro R, Lee JH, Loman JC, Rossman MD, Alavi A: Do high glucose levels have differential effect on FDG uptake in inflammatory and malignant disorders? Nucl Med Commun 2001, 22(10):1123-1128.
6. Gorenberg M, Hallett WA, O'Doherty MJ: Does diabetes affect [(18)F]FDG standardised uptake values in lung cancer? Eur J Nucl Med Mol Imaging 2002, 29(10):1324-1327.
7. Eary JF, Mankoff DA: Tumor metabolic rates in sarcoma using FDG PET. J Nucl Med Offic Publ, Soc Nucl Med 1998, 39(2):250-254.
8. Young WG, Deutsch JA: Effects of blood glucose levels on [14C]2-deoxyglucose uptake in rat brain tissue. Neurosci Lett 1980, 20(1):89-93.
9. Hallett WA, Marsden PK, Cronin BF, O'Doherty MJ: Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 2001, 28(7):919-922.
10. Hadi M, Bacharach SL, Whatley M, Libutti SK, Straus SE, Rao VK, Wesley R, Carrasquillo JA: Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV. Nucl Med Biol 2008, 35(4):441-445.
11. Crouthamel MC, Kahana JA, Korenchuk S, Zhang SY, Sundaresan G, Eberwein DJ, Brown KK, Kumar R: Mechanism and management of AKT inhibitor-induced hyperglycemia. Clin Can Res Offic J Am Assoc Canc Res 2009, 15(1):217-225.
12. Gallagher EJ, Fierz Y, Vijayakumar A, Haddad N, Yakar S, Leroith D: Inhibiting PI3K reduces mammary tumor growth and induces hyperglycemia in a mouse model of insulin resistance and hyperinsulinemia. Oncogene 2011. doi: 10.1038/onc.2011.495.
13. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M: The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977, 28(5):897-916.
14. Williams SP, Flores-Mercado JE, Port RE, Bengtsson T: Quantitation of glucose uptake in tumors by dynamic FDG-PET has less glucose bias and lower variability when adjusted for partial saturation of glucose transport. EJNMMI Res 2012, 2(1):6.
15. Gottesman I, Mandarino L, Verdonk C, Rizza R, Gerich J: Insulin increases the maximum velocity for glucose uptake without altering the Michaelis constant in man. Evidence that insulin increases glucose uptake merely by providing additional transport sites. J Clin Investig 1982, 70(6):1310-1314.
16. Kuwabara H, Evans AC, Gjedde A: Michaelis-Menten constraints improved cerebral glucose metabolism and regional lumped constant measurements with [18F]fluorodeoxyglucose. J Cereb Blood Flow Metab 1990, 10(2):180-189.
17. Yki-Jarvinen H, Young AA, Lamkin C, Foley JE: Kinetics of glucose disposal in whole body and across the forearm in man. J Clin Investig 1987, 79(6):1713-1719.
18. Burrows RC, Freeman SD, Charlop AW, Wiseman RW, Adamsen TC, Krohn KA, Spence AM: [18F]-2-fluoro-2-deoxyglucose transport kinetics as a function of extracellular glucose concentration in malignant glioma, fibroblast and macrophage cells in vitro. Nucl Med Biol 2004, 31(1):1-9.
19. Rivenzon-Segal D, Rushkin E, Polak-Charcon S, Degani H: Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells. Am J Physiol Endocrinol Metab 2000, 279(3):E508-E519.
20. Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J 2000, 351(Pt 2):289-305.
21. Thompson N, Lyons J: Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 2005, 5(4):350-356.
22. Williams SP, Fredrickson J, Mckenzie M, Jones C, Gates M, Hoeflich K, LoRusso P, Rosen L, Sikic B, Ma W, Chan I, de Crespigny AJ: Preclinical and clinical evidence for MEK pathway inhibition by GDC-0973 using FDG-PET. Presentation 1280/5 In Proceedings of the American Association for Cancer Research 102nd Annual Meeting: April 2-6 2011; Orlando.
23. McArthur GA, Puzanov I, Ribas A, Chapman PB, Kim KB, Sosman JA: Early FDGPET responses to PLX4032 in BRAF-mutant advanced melanoma [abstract]. J Clin Oncol 2010, 28:15s.
24. Carlino MS, Saunders CA, Gebski V, Menzies AM, Ma B, Lebowitz PF: Heterogeneity of FDG-PET response to GSK2118436, an inhibitor of oncogenic mutant BRAF-kinase in BRAF-mutant metastatic melanoma [abstract]. J Clin Oncol 2011, 29.
25. Flores JE, McFarland LM, Vanderbilt A, Ogasawara AK, Williams SP: The effects of anesthetic agent and carrier gas on blood glucose and tissue uptake in mice undergoing dynamic FDG-PET imaging: sevoflurane and isoflurane compared in air and in oxygen. Mol Imag Biol 2008, 10(4):192-200.
26. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R, Cancer Genome Project: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116(6):855-867.
27. Zhang BH, Guan KL: Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 2000, 19(20):5429-5439.
28. Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, Stern H, Choo E, Murray L, Friedman L, Belvin M: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res 2009, 69(7):3042-3051.
29. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman L, Lackner M: In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009, 15(14):4649-4664.
30. R Development Core Team: R: A Language and Environment for Statistical Computing. Vienna: R Foundation for Statistical Computing; 2011.
31. Rice J: Power. Mathematical Statistics and Data Analysis. Belmont: Duxbury Press; 1995.
32. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE: Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979, 6(5):371-388.
33. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J, Hoekstra OS, Pruim J, Marsden PK, Tatsch K, Hoekstra CJ, Visser EP, Arends B, Verzijlbergen FJ, Zijlstra JM, Comans EF, Lammertsma AA, Paans AM, Willemsen AT, Beyer T, Bockisch A, Schaefer-Prokop C, Delbeke D, Baum RP, Chiti A, Krause BJ: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging 2010, 37(1):181-200.
34. Arnold SF: Inferences in Multiple Regression. Mathematical Statistics. NJ: Prentice-Hall; 1990.
35. Christensen R: Plane Answers to Complex Questions: The Theory of Linear Models. 1st ed. New York: Springer; 1987.